Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Market Update

Julia Lee
July 26, 2017

Market Update

Julia Lee
July 25, 2017

Market Update

Julia Lee
July 24, 2017

Market Update

Julia Lee
July 21, 2017

Market Update

Julia Lee
July 21, 2017

Market Update

Julia Lee
July 20, 2017

Market Update

Julia Lee
July 18, 2017

Market Update

Julia Lee
July 17, 2017

Market Update

Julia Lee
July 14, 2017

Market Update

Julia Lee
July 13, 2017

Market Update

Julia Lee
July 12, 2017